{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:38:47Z","timestamp":1773059927643,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.gtc.2023.05.008","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T15:53:18Z","timestamp":1687276398000},"page":"589-597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The State of Clinical Trials in Pediatric Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"52","author":[{"given":"Jeffrey S.","family":"Hyams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard K.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2023.05.008_bib1","first-page":"S1","article-title":"The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada","volume":"2","author":"Benchimol","year":"2019","journal-title":"J\u00a0Can Assoc Gastroenterol"},{"key":"10.1016\/j.gtc.2023.05.008_bib2","first-page":"619","article-title":"Prevalence of Inflammatory Bowel Disease in Pediatric and Adult Populations: Recent Estimates From Large National Databases in the United States, 2007-2016","volume":"26","author":"Ye","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2023.05.008_bib3","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2023.05.008_bib4","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/ajg.2009.177","article-title":"The natural history of pediatric ulcerative colitis: a population-based cohort study","volume":"104","author":"Gower-Rousseau","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2023.05.008_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13645","article-title":"Systematic review: psychological morbidity in young people with inflammatory bowel disease - risk factors and impacts","volume":"44","author":"Brooks","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2023.05.008_bib6","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","article-title":"Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease","volume":"135","author":"Van Limbergen","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2023.05.008_bib7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ajhg.2009.01.026","article-title":"Diverse genome-wide association studies associate the IL12\/IL23 pathway with Crohn Disease","volume":"84","author":"Wang","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.gtc.2023.05.008_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/MPG.0000000000001898","article-title":"Molecular Comparison of Adult and Pediatric Ulcerative Colitis Indicates Broad Similarity of Molecular Pathways in Disease Tissue","volume":"67","author":"Li","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gtc.2023.05.008_bib9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gtc.2023.05.008_bib10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and Maintenance Therapy with Infliximab for Children with Moderate-to-Severe Ulcerative Colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2023.05.008_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2023.05.008_bib12","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-052501","article-title":"Delays Related to Prior Authorization in Inflammatory Bowel Disease","volume":"149","author":"Constant","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.gtc.2023.05.008_bib13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/MPG.0000000000003564","article-title":"Denials, Dilly-dallying, and Despair: Navigating the Insurance Labyrinth to Obtain Medically Necessary Medications for Pediatric Inflammatory Bowel Disease Patients","volume":"75","author":"Kahn","year":"2022","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gtc.2023.05.008_bib14","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/jgh3.12684","article-title":"Factors associated with time to clinical remission in pediatric luminal Crohn's disease: A retrospective cohort study","volume":"5","author":"Sassine","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.gtc.2023.05.008_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.14309\/ajg.0000000000001650","article-title":"Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease: A Retrospective Cohort Study","volume":"117","author":"Sassine","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2023.05.008_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","article-title":"Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease","volume":"146","author":"Walters","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2023.05.008_bib17","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1097\/MPG.0000000000003190","article-title":"Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease","volume":"73","author":"Moore","year":"2021","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gtc.2023.05.008_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0000000000002362","article-title":"Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center","volume":"69","author":"Dayan","year":"2019","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.gtc.2023.05.008_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/ecco-jcc\/jjac135","article-title":"Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents","volume":"17","author":"Croft","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gtc.2023.05.008_bib20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2023.05.008_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2125.2000.00125.x","article-title":"Drug trials in children: problems and the way forward","volume":"49","author":"Conroy","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.gtc.2023.05.008_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2022.03.018","article-title":"Pediatric Extrapolation of Adult Efficacy to Children Is Critical for Efficient and Successful Drug Development","volume":"163","author":"Mulberg","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2023.05.008_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S2468-1253(21)00142-4","article-title":"Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study","volume":"6","author":"Croft","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2023.05.008_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/gutjnl-2018-317987","article-title":"Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary","volume":"69","author":"Turner","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2023.05.008_bib25","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/01.MIB.0000435438.84365.f7","article-title":"Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study","volume":"19","author":"Adedokun","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2023.05.008_bib26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","article-title":"Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study","volume":"21","author":"Sharma","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.gtc.2023.05.008_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(22)00307-7","article-title":"Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study","volume":"8","author":"Atia","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2023.05.008_bib28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s43441-022-00448-3","article-title":"The Role of Master Protocols in Pediatric Drug Development","volume":"56","author":"Nelson","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.gtc.2023.05.008_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cgh.2019.04.012","article-title":"Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease","volume":"18","author":"Cozijnsen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2023.05.008_bib30","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855323000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855323000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:40:45Z","timestamp":1760179245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855323000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0889855323000596"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2023.05.008","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The State of Clinical Trials in Pediatric Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2023.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}